Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD

Video

The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies Program, physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, about the uptake of novel therapies in heavily pretreated multiple myeloma.

Nadeem discussed how therapeutic additions are welcome in the setting of heavily relapsed/refractory multiple myeloma. Although frontline therapies are prolonging life, multiple myeloma remains incurable and more patients progress to triple-class refractory disease, Nadeem explains.

Novel therapies, such as selinexor (Xpovio), belantamab mafodotin-blmf (Blenrep), melphalan flufenamide (Pepaxto), and idecabtagene vicleucel (Abecma), are available options for patients who have progressed on an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody, Nadeem explains.

Treatment decisions should be based on the unique mechanisms of action of these agents, differences in administration, and potential toxicities, Nadeem says. Additionally, patient factors, such as frailness, oral vs intravenous therapy preference, and renal function, should be taken into consideration when selecting treatment, concludes Nadeem.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.